NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT
Post# of 151
(Total Views: 121)
Posted On: 09/26/2023 5:15:59 PM
NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Leaders to New Senior Management Positions
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home allowing for the creation of rich data for AI, has appointed two new team leaders. The company announced that Richa Gujarati will serve as senior vice president over product, and Pooja Chatterjee will be vice president over clinical. The two positions are designed to support clinical development and commercialization of HeartBeam’s ambulatory VECG products. With more than 13 years of experience collecting market-level insights and translating those insights into business needs, Gujarati has an impressive background in overall product portfolio and go-to-market strategy. She has served as VP of product & go-to-market strategy at NextSense; head of health products, Apple Watch, at Apple; and senior manager, product management & marketing, at iRhythm Technologies. Chatterjee has garnered more than 15 years of clinical leadership experience in the medical device industry and has shouldered a wide range of clinical responsibilities, including field engineering, clinical portfolio strategy and study execution resulting in multiple FDA approvals. She held several positions at Abbott Medical Devices, most recently as global clinical project director.
According to the announcement, Gujarati will have direct responsibility for HeartBeam’s product road map and go-to-market strategy and execution while Chatterjee will be responsible for strategic and tactical leadership of the clinical pipeline, with the objective of securing FDA clearances to support commercialization. “We welcome Richa and Pooja to HeartBeam’s leadership team and look forward to leveraging their extensive experience to help bring our ambulatory VECG products to market,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “Richa’s deep expertise in go-to-market strategies for health-sensing technologies will be instrumental as we ready the HeartBeam AIMIGo VECG device for limited market release during the second half of 2024. Pooja will play a pivotal role leading the validation of our technologies, including FDA 510(k) clearance for the HeartBeam AIMIGo VECG device and post-market regulatory required studies. Together they will add to our growing team of medical and technology experts as we progress toward our initial clearances and the commercial availability of our technology.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home allowing for the creation of rich data for AI, has appointed two new team leaders. The company announced that Richa Gujarati will serve as senior vice president over product, and Pooja Chatterjee will be vice president over clinical. The two positions are designed to support clinical development and commercialization of HeartBeam’s ambulatory VECG products. With more than 13 years of experience collecting market-level insights and translating those insights into business needs, Gujarati has an impressive background in overall product portfolio and go-to-market strategy. She has served as VP of product & go-to-market strategy at NextSense; head of health products, Apple Watch, at Apple; and senior manager, product management & marketing, at iRhythm Technologies. Chatterjee has garnered more than 15 years of clinical leadership experience in the medical device industry and has shouldered a wide range of clinical responsibilities, including field engineering, clinical portfolio strategy and study execution resulting in multiple FDA approvals. She held several positions at Abbott Medical Devices, most recently as global clinical project director.
According to the announcement, Gujarati will have direct responsibility for HeartBeam’s product road map and go-to-market strategy and execution while Chatterjee will be responsible for strategic and tactical leadership of the clinical pipeline, with the objective of securing FDA clearances to support commercialization. “We welcome Richa and Pooja to HeartBeam’s leadership team and look forward to leveraging their extensive experience to help bring our ambulatory VECG products to market,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “Richa’s deep expertise in go-to-market strategies for health-sensing technologies will be instrumental as we ready the HeartBeam AIMIGo VECG device for limited market release during the second half of 2024. Pooja will play a pivotal role leading the validation of our technologies, including FDA 510(k) clearance for the HeartBeam AIMIGo VECG device and post-market regulatory required studies. Together they will add to our growing team of medical and technology experts as we progress toward our initial clearances and the commercial availability of our technology.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Heartbeam Inc. (BEAT) Stock Research Links
Scroll down for more posts ▼